enVVeno Medical Corporation has reported its financial results for the third quarter of 2025, revealing a net loss of $4.5 million, a decrease of 20% from the $5.6 million loss recorded in the same period of 2024. The company attributed this reduction primarily to a decrease in operating expenses, which fell by $1.3 million, despite a slight decline in other income. For the nine months ending September 30, 2025, the net loss was $15.7 million, a marginal increase from the $15.6 million loss reported for the same period in 2024. The company continues to operate without generating revenue, as it remains focused on the development and commercialization of its lead product, the VenoValve.
In terms of operational metrics, enVVeno Medical's research and development expenses for the third quarter decreased by 10% to $2.6 million, primarily due to reduced costs associated with the VenoValve pivotal study. Selling, general, and administrative expenses also saw a significant decline of 31%, totaling $2.3 million, largely due to the absence of non-recurring legal costs that impacted the previous year. The company’s total assets decreased to $32.4 million as of September 30, 2025, down from $44.9 million at the end of 2024, reflecting a reduction in cash and short-term investments.
The company has made strategic advancements in its product pipeline, particularly with the VenoValve, which is currently in the post-enrollment follow-up phase of its pivotal study. The VenoValve aims to address severe Chronic Venous Insufficiency (CVI) and has received Breakthrough Device designation from the FDA. However, enVVeno Medical faced a setback in August 2025 when it received a not-approvable letter from the FDA regarding its Premarket Approval (PMA) application for the VenoValve. The company has since filed for a supervisory appeal, seeking to address the FDA's concerns regarding the clinical data and safety profile of the device.
As of September 30, 2025, enVVeno Medical had a cash and investment balance of approximately $31 million, with working capital of $29.1 million. The company anticipates that its cash burn rate will increase to between $5 million and $7 million per quarter as it continues its clinical trials and prepares for commercialization efforts. The company is also awaiting clarity from the FDA regarding its enVVe product, a next-generation non-surgical replacement venous valve, before proceeding with its Investigational Device Exemption (IDE) application, which is expected to be filed in early 2026.
Looking ahead, enVVeno Medical remains focused on advancing its clinical programs and addressing regulatory challenges. The company believes its current capital resources are sufficient to meet its obligations for at least the next year, although it acknowledges the need for additional capital to support ongoing operations and product development initiatives. The outcome of the FDA appeal and the progress of its clinical trials will be critical in determining the company's future trajectory and potential market entry for its innovative medical devices.
About enVVeno Medical Corp
enVVeno Medical Corporation is a late-stage medical device company developing bioprosthetic solutions for venous disease, primarily focusing on chronic venous insufficiency. Its flagship products, VenoValve and enVVe, are designed as surgical and non-surgical venous valves to treat severe deep venous conditions. The company aims to improve patient outcomes and reduce healthcare costs through innovative, tissue-based implantable devices targeting a large, underserved market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.